CS
MLNT

Credit Suisse’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Credit Suisse’s Portfolio MLNT Stock Details MLNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-91,311
Closed -$607K – 4340
2019
Q2 		$607K Buy
+91,311
New +$348K ﹤0.01% 3287

Other funds holding MLNT

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Credit Suisse's MLNT Position: Q3 2019 in Review

Credit Suisse sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q3 2019, closing a stake of 91,311 shares — an estimated $607K sold.

Credit Suisse first reported a position in MLNT in Q2 2019 and held it in 1 quarter. The position peaked at $607K in Q2 2019. 47 funds tracked by Wall St. Rank hold MLNT as of Q3 2019.

  • Credit Suisse reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
  • Credit Suisse sold 91,311 Melinta Therapeutics, Inc. Common Stock shares in Q3 2019, an estimated $607K.
  • Credit Suisse first reported a position in Melinta Therapeutics, Inc. Common Stock in Q2 2019 and held it in 1 quarter.
  • Credit Suisse's Melinta Therapeutics, Inc. Common Stock position peaked at $607K in Q2 2019.
  • 47 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q3 2019.

Based on Credit Suisse's 13F filing for Q3 2019, filed 12 Nov 2019.